The largest ever study of its kind has become the first to definitively show an increased risk of blood cancers in relatives of patients.
Browsing: Disease Area > Hematologic
A multi-disciplinary team of researchers have developed comprehensive CAR T-cell therapy pediatric guidelines.
The FDA has approved TIBSOVO – the first oral, targeted therapy for relapsed/ refractory acute myeloid leukemia (R/R AML) adults patients and an IDH1 mutation.
This database study demonstrates variations in the utilization of hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia based on several biological and non-biological factors.
Researchers have discovered that it is possible to identify individuals at high risk of developing acute myeloid leukaemia years before diagnosis.
Find out about the healthcare utilization and costs associated with diffuse large B-cell & follicular lymphoma patients treated in the US in this research article from Future Oncology.
A major new analysis has revealed, for the first time, a possible cause for most cases of acute lymphoblastic leukemia and has discovered that it is likely to be preventable.
In this review article find out which treatment plan is most appropriate for different groups of acute lymphoblastic leukemia patients.
In this interview discover some of the challenges in developing CAR-T therapies for solid tumors as well as major milestones in their development and where the field is heading.